1. AMN plans to offer $400 million in senior unsecured notes due 2031. 2. Proceeds will redeem $500 million of existing senior notes due 2027. 3. Offering contingent on successful sale of the 2031 Notes. 4. This move aims to optimize AMN's capital structure. 5. The company serves 15 million patients annually through a vast network.
Redeeming higher interest notes with new lower-interest debt will reduce financial costs, enhancing profitability. Previous initiatives to optimize debt structures have often led to improved stock performance in similar companies.
This corporate action directly influences AMN's debt cost structure, a crucial factor for profitability and stability.
The immediate impact from the offering and redemption process is likely to be realized in the next quarter as investors will respond to reduced interest expenses and enhanced financial health.
DALLAS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE:AMN), announced today that its wholly owned subsidiary, AMN Healthcare, Inc., intends to make a private offering of $400.0 million aggregate principal amount of senior unsecured notes due 2031, subject to market and other conditions. The 2031 Notes will be guaranteed by the Company's affiliates that guarantee the Company's credit facilities.
The Company intends to use the proceeds from the private offering, together with cash on hand and borrowings under the Company's secured revolving credit facility, (i) to redeem all of the $500.0 million aggregate principal amount of its 4.625% senior unsecured notes due 2027 outstanding and (ii) to pay fees and expenses related to the offering.
The Company expects to deliver a Conditional Notice of Redemption to holders of its outstanding 2027 Notes, which will provide for the redemption by the Company of all of the $500.0 million aggregate principal amount of 2027 Notes outstanding, subject to the successful completion of offering of the 2031 Notes.
The 2031 Notes will be offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended, and to non-U.S. persons outside of the United States in compliance with Regulation S under the Securities Act. The 2031 Notes will not be registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the 2031 Notes, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.
About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare, bringing together the people, processes and technology to deliver better care. Through a steadfast partnership approach, we solve the most pressing workforce challenges to enable better clinical outcomes and access to care. In 2024, our healthcare professionals reached nearly 15 million patients at more than 2,100 healthcare systems, including 87 percent of the top healthcare systems nationwide. We provide a comprehensive network of quality healthcare professionals and deliver a fully integrated and customizable suite of workforce technologies.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "should," "would," "project," "may," "estimates," variations of such words and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Factors that could cause actual results to differ from those implied by the forward-looking statements contained in this press release are set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and its other periodic reports as well as the Company's current and other reports filed from time to time with the Securities and Exchange Commission. Be advised that developments subsequent to this press release are likely to cause these statements to become outdated.
Contact:
Randle Reece
Vice President, Investor Relations & Strategy
866-861-3229
